Has Sarah Rosenfield received payments from drug or device companies?

Yes. Drug and device makers reported $6,205 in general payments to Sarah Rosenfield across 264 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Sarah Rosenfield did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Sarah Rosenfield come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Sarah Rosenfield

Family · Wynnewood, PANPI 1457128506

Payments from drug & device makers

$6,205in general payments, 2019–2025

Across 264 payments — averaging $23.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$639
Novartis$557
Genentech USA, Inc.$400
Incyte Corporation$399
Johnson & Johnson$390
Astellas Pharma US Inc$262
plus $4K from 46 others

What the payments were for

Food & beverage$5,93296%
Education$2734%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca(2 entities)	26	$639
Novartis	24	$557
Genentech USA, Inc.	17	$400
Incyte Corporation	20	$399
Johnson & Johnson	18	$390
Astellas Pharma US Inc	6	$262
Daiichi Sankyo Inc.	10	$261
Bayer	11	$254
Eisai Inc.	10	$245
Takeda Pharmaceuticals U.S.A., Inc.	9	$214
Merck	8	$172
Tempus AI, Inc	6	$150
Sanofi	5	$144
Bristol Myers Squibb	5	$127
Sobi, Inc	6	$120
AbbVie	5	$111
Ipsen Biopharmaceuticals, Inc	4	$108
Novocure Inc.	4	$107
Genmab U.S., Inc.	4	$103
Pharmacosmos Therapeutics Inc.	5	$91
Gilead(2 entities)	4	$86
Stemline Therapeutics Inc.	4	$84
Beigene USA, Inc.	3	$78
Regeneron Healthcare Solutions, Inc.	3	$76
Beone Medicines USA, Inc.	3	$70
Puma Biotechnology, Inc.	3	$67
Array Biopharma Inc	3	$62
GSK	2	$61
Pfizer	3	$58
Tersera Therapeutics LLC	3	$55
Legend Biotech USA Inc.	2	$55
Sumitomo Pharma America, Inc.	3	$52
Pharmaessentia USA Corporation	2	$49
Adaptive Biotechnologies Corporation	2	$49
Lilly USA, LLC	2	$46
Rigel Pharmaceuticals, Inc.	2	$41
Immunocore Limited	1	$37
EMD Serono, Inc.	2	$34
E.r. Squibb & Sons, L.L.C.	1	$32
Immunogen, Inc.	1	$30
Agios Pharmaceuticals, Inc.	1	$26
Boehringer Ingelheim	1	$25
Jazz Pharmaceuticals Inc.	1	$22
Myriad Genetic Laboratories, Inc.	1	$21
Mirati Therapeutics, Inc.	1	$20
Recordati_rare_diseases_inc.	1	$20
Progenics Pharmaceuticals, Inc.	1	$20
Iovance Biotherapeutics, Inc.	1	$18
Geron Corporation	1	$15
Cumberland Pharmaceuticals, Inc.	1	$15
Secura Bio, Inc.	1	$15
Coherus Oncology, Inc.	1	$14

How this compares

$6,205 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$269,683

Medicare patients

181

Services billed

30,234

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OxycontinOxycodone Hcl	11	$17,203
Oxycodone Hcl	56	$931
Dexamethasone	33	$856
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	12	$750
Morphine Sulfate ErMorphine Sulfate	25	$426
Prochlorperazine Maleate	29	$409
Hydromorphone Hcl	11	$234
Ondansetron Hcl	28	$205
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine	22	$186
Acyclovir	23	$165
Lorazepam	23	$117
Zolpidem Tartrate	15	$105

Paid to pharmacies, not to this prescriber.

Other family in Wynnewood

Jacqueline McGeeWynnewood$17K
Kathleen ScholzPittsburgh$397K
Shannon FitzgeraldAllison Park$370K
Stephanie HarshbargerCamp Hill$317K
Whitney BowlesFort Washington$253K
Kweilynn GreenePittsburgh$139K
Jessica LindenbergerPittsburgh$131K
Kami NestlerWilkes Barre$129K
Bethany ThomasPhiladelphia$126K
Margaret RosenzweigPittsburgh$89K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →